Nammi Therapeutics, Inc.

About Nammi Therapeutics, Inc.

Nammi Therapeutics, Inc. is a company focused on advancing immuno-oncology by developing products that target immune activation specifically at tumor sites, minimizing the severe side effects associated with systemic immune activation.

Products & Services

QXL138AM:An anti-CD138 targeting antibody fused to IFNa2 cytokine with a masking peptide attached via a protease cleavable linker, part of the Masked ImmunoCytokines (MICs) platform.

SLNP-IC1:A Solid Lipid Nanoparticle incorporating a Doxorubicin prodrug (IC1), part of the Nammisomes platform.

Specialties

Masked ImmunoCytokines (MICs) Nammisomes Tumor-targeted Immunotherapy Oncology Drug Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 30000000 MR: - FA: $30M FAN: 30000000	D: 2024-08-06 FD: 2024-08-06	1 investors

Series B Latest

2024-08-06

$30.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David Stover

Founder and CEO

S

Sherie Morrison

Senior Scientific Advisor

J

Joseph Rice

EVP of Operations

D

Donald B. Rice

G

George Ayoub

K

Kenan Turnacioglu

Chairperson

View 3 more team members with Pro

Unlock Full Team Directory

Recent News